Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of autologous bio-engineered dermo-epidermal skin substitute (EHSG-KF) versus split-thickness skin grafts
2017-002462-41Phase 2Active
- Sponsor
- CUTISS
- Start
- Apr 2018
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of denovoSkin in Skin and connective tissue disease (2 arms), sponsored by CUTISS. Primary endpoint: Primary efficacy and safety of EHSG-KF versus STSG. Started Apr 2018; status: active.
02
Drugs
denovoSkin
03
Conditions
Skin and connective tissue disease
Beyond the preview
Go deeper on 2017-002462-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002462-41.